Adjuvant treatment for early rectal cancer after local removal
Part of Cancer, Digestive system clinical trials.
This study looks at whether giving radiation or chemoradiation after removing an early-stage rectal cancer can improve outcomes for patients who choose not to have standard surgery to remove the whole rectum. It aims to see how well this approach works in real-world practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with a type of rectal cancer that has grown into the submucosa (the layer just beneath the surface) but has not spread to lymph nodes or other organs.
- You have had the cancer removed through a local procedure (like endoscopic submucosal dissection or transanal endoscopic microsurgery) and the pathology shows certain high-risk features.
- You are willing to start radiation or chemoradiation within 12 weeks after the surgery.
- You have declined the standard surgery (total mesorectal excision) after your surgeon explained it to you.
- You have not had prior rectal surgery or pelvic radiation, and you do not have other cancers in the last 5 years, inflammatory bowel disease, or hereditary colorectal cancer syndromes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares standard chemotherapy to more extensive surgery (total mesorectal excision) for patients whose initial local surgery showed high-risk features like poor differentiation, lymphovascular invasion, or larger tumor size. It aims to find the best treatment to prevent cancer from coming back.
This study compares two approaches after early-stage rectal cancer is removed: either careful monitoring or a follow-up treatment with chemotherapy and radiation. The goal is to see which strategy works better to keep the cancer from returning.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
This trial tests whether a full course of chemotherapy and radiation before any surgery (called total neoadjuvant therapy) can help you avoid surgery and preserve your rectum. It is for people with a specific early stage of rectal cancer that has not spread.
This trial tests a short course of radiation given before chemotherapy for people with locally advanced rectal cancer (cancer that has grown into nearby tissue and/or nearby lymph nodes but can still be removed). It may help shrink the tumor and make treatment more effective while assessing how well this approach works.
This trial tests whether people with early- to intermediate-stage low rectal cancer can avoid surgery if their tumor responds well to a full course of chemotherapy and radiation. It starts with brief chemotherapy, then adjusts treatment based on how much the tumor shrinks.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.